BPS 2023 Proceedings

WALEED DANHO YOUNG INVESTIGATOR AWARD

Helena Safavi-Hemami

Associate Professor
University of Utah

Venom-inspired design of novel peptide drug leads for diabetes and pain

Past Young Investigator Award Update Lecture

Research update from a past recipient of the Danho Young Investigator Award.

Albert Bowers

Associate Professor
UNC Chapel Hill

Enabling Genetic Code Expansion and Peptide Macrocyclization in mRNA Display via a Promiscuous Orthogonal Aminoacyl-tRNA Synthetase

Peptide Showcase

Brief 15 minute presentations from companies developing peptide therapeutics and related technologies. This rapid and compressed format is designed for quick introduction between symposium participants to new technologies, and companies. Each presentation is structured to highlight the value of the technology or therapeutic being offered and the business strategy.

Marina Buyanova

Principal Scientist
Grove Biopharma, Inc.

Protein-like Polymers – Designer Proteomimetics for Intracellular Targets

Paul Wright

VP-CMC
MBX Biosciences

Precision Endocrine Peptides (PEPs) – from Hormones to Innovative Medicines

Derek Cole

Founder & CEO
Ferdia Therapeutics

Discovery of best-in-class long-acting peptide drugs for clinically validated targets.

Ewa Lis

CEO
Koliber Biosciences Inc.

Zero shot (no training data) machine learning approaches for protein and peptide optimization.

Kristian Strømgaard

Professor, CEO
University of Copenhagen

Targeting Intracellular Protein-Protein Interactions with Therapeutic Peptides

Caitlyn Miller

Entrepreneur-In-Residence
Stanford University

Delivering Immunotherapy to Solid Tumors using an Engineered Peptide-Immunostimulant Conjugate

Geeta Meher

Associate Director, Discovery Chemistry
PepGen

Enhanced Delivery Oligonucleotide Platform for Neuromuscular Diseases

Anthony Maida

Founder, Chairman and CEO
T-NanoBio Therapeutics, Inc.

Transformable Smart Peptides as Cancer Therapeutics

Natalia Zisman

Director of Chemistry, Manufacturing and Controls
Concarlo Therapeutics

A p27-targeting novel peptide inhibitor to address drug resistance of tumors

Peptides in the Clinic (Sponsored by Anaspec)

Updates on clinical development of peptide therapeutics.

Pravin Kaumaya

Professor of Medicine and Director Vaccine Research
Indiana University

Translating B-cell epitope peptide cancer vaccines into clinical immunotherapies and combinations in Immuno-Oncology.

Richard Liggins

Chief Scientific Officer
Zucara Therapeutics

ZT-01, a novel SSTR2 antagonist to prevent nocturnal hypoglycemia in insulin dependent diabetes: results from Phase 1 studies and dose selection for a Phase 2 study in Type 1 diabetes (T1D).

Michael Neely

Consultant
Xeris Pharmaceuticals Inc.

XeriSol: A non-aqueous peptide formulation approach for enhanced stability and solubility

Jan Johansson

CEO
Artery Therapeutics, Inc.

A novel small molecule peptide CS6253 in the treatment of hereditary APOE4-associated dementia including Alzheimer’s disease

Dieter Willbold

Director
Forschungszentrum Jülich

All-D-peptides realize the purely thermodynamic anti-prionic mode of action for protein-misfolding diseases

Drug Delivery

Novel approaches to peptide drug delivery including devices, molecular engineering, conjugation, and formulation technologies

Karsten Lindhardt

CEO
Biograil

BIONDD™ for Oral Delivery of Biologics – Effective Gastric Mucosal Delivery of Macromolecules – Go BIONDD™

Joel Schneider

Chief of Chemical Biology
Center for Cancer Research, NCI

Peptide Materials from Self-Assembly and their Use in Therapy

Adam Mendelsohn

CEO
Vivani Medical, Inc.

A twice-yearly, miniaturized, subdermal GLP-1 implant being developed to guarantee medication adherence and improve real world outcomes in the treatment of Type 2 Diabetes and Obesity